Patents Examined by Michail A Belyavskyi
  • Patent number: 11866688
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: January 9, 2024
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Cecile Chartier-Courtaud, Krit Ritthipichai
  • Patent number: 11845959
    Abstract: Transient MLLT3 overexpression in culture may be used to expand human HSCs in vitro, and thereby improve the efficiency and safety of HSC transplantation.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 19, 2023
    Assignee: The Regents of the University of California
    Inventors: Hanna Mikkola, Vincenzo Calvanese, Andrew T. Nguyen
  • Patent number: 11833218
    Abstract: Described herein are biomimetic Janus particles useful as artificial antigen presenting cells capable of activating T cells in vitro. “Bull's eye” ligand patterns mimicking either the native or reverse organization of the T cell immunological synapse are provided on the surface of nano- or micro-sized particles. Methods for activating T cells in vitro using biomimetic Janus particles described herein are also provided. T cells activated by the biomimetic Janus particles can be used in adoptive immunotherapies for treating cancer, tolerance induction in autoimmune disease, autologous immune enhancement therapy, and viral infection immunotherapy. Also described herein are methods for producing a biomimetic Janus particle.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: December 5, 2023
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Yan Yu
  • Patent number: 11802269
    Abstract: The disclosure provides a method of producing modified stem memory T cells (e.g. CAR-T cells) for administration to a subject as, for example an adoptive cell therapy.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 31, 2023
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric M. Ostertag, Devon Shedlock
  • Patent number: 11773373
    Abstract: Disclosed is a method for rapidly amplifying CD8+T cells and functional cell subpopulations thereof in vitro. A TLR1/2 agonist, a TLR2/6 agonist and a TLR5 agonist or a combination of above agonists is added to a conventional culture system for in-vitro amplification of CD8+T cells. Recombinant cytokines IL-2, IL-7 and IL-15 as well as magnetic beads coated with an anti-human CD3 antibody and an anti-human CD28 antibody can be further added to the culture system for continuous co-stimulation.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: October 3, 2023
    Assignee: Shanghai Innovative Chang'An Biological Technology Co., Ltd.
    Inventors: Jianqing Xu, Xiaoyan Zhang, Chenli Qiu
  • Patent number: 11739298
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: August 29, 2023
    Assignee: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Patent number: 11725187
    Abstract: It is provided a method of expanding ex vivo hematopoietic stem cells (HSC), the method comprising selecting a population of Endothelial Protein C Receptor (EPCR)+ HSC, culturing the selected HSC thereby expanding said EPCR+ HSC and the use of the expanded EPCR+ HSC for stem cells transplantation.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 15, 2023
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Iman Fares, Jalila Chagraoui
  • Patent number: 11702635
    Abstract: A method to expand hematopoietic stem and progenitor cells (HSPC) wherein the method comprises obtaining an isolated population of HSPC the culturing the isolated population of HSPC in the presence of a histone deacetylase inhibitor (HDAC inhibitor), to form a cultured population, then adding an aminothiol compound to the cultured population.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: July 18, 2023
    Assignee: PLASTICELL LIMITED
    Inventor: Diana Hernandez
  • Patent number: 11673958
    Abstract: The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: June 13, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Silke Hansen, Klaus-Peter Kuenkele, Dietmar Reusch, Ralf Schumacher
  • Patent number: 11661598
    Abstract: A method of screening is provided. In certain embodiments, the method involves a) obtaining the nucleotide sequences of: i. a heavy chain-encoding nucleic acid that encodes the variable domain of a heavy chain of a first antibody of an animal; and ii. a light chain-encoding nucleic acid that encodes the variable domain of a light chain of the first antibody; b) obtaining nucleotide sequences of cDNAs encoding at least a portion of the antibody repertoire of the animal; c) computationally screening the sequences obtained in b) to identify heavy and light chain sequences that are related by lineage to the heavy and light chain sequences of a); and d) testing at least one pair of the heavy and light chain sequences identified in c) to identify a second antibody that binds to the same antigen as the first antibody.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: May 30, 2023
    Assignee: EPITOMICS, INC.
    Inventors: Mark Bushfield, Michael Hadjisavas, Luc Adam
  • Patent number: 11661579
    Abstract: Methods of culturing cells capable of producing desired proteins to obtain the proteins by use of a medium from which biological components are excluded as much as possible are provided. Specifically, a culture method characterized by culturing while maintaining a specific amino acid in a culture solution at a high concentration, and a cell culture fed-batch medium for use in the method are provided.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: May 30, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Satoshi Katayama, Shouhei Kishishita, Kunihiko Kodaira, Makoto Sadamitsu, Yoshinori Takagi, Hiroki Matsuda
  • Patent number: 11648293
    Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 16, 2023
    Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.
    Inventors: Amnon Peled, Yaron Pereg
  • Patent number: 11648264
    Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 16, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel Strober, Robert Lowsky
  • Patent number: 11648278
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: August 3, 2022
    Date of Patent: May 16, 2023
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 11642393
    Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 9, 2023
    Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.
    Inventors: Amnon Peled, Yaron Pereg
  • Patent number: 11638742
    Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 2, 2023
    Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.
    Inventors: Amnon Peled, Yaron Pereg
  • Patent number: 11638743
    Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 2, 2023
    Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.
    Inventors: Amnon Peled, Yaron Pereg
  • Patent number: 11618885
    Abstract: This invention relates to the expansion of non-haematopoietic tissue-resident ?? T cells in vitro by culturing lymphocytes obtained from non-haematopoietic tissue of humans or non-human animals in the presence of interleukin-2 (IL-2) and/or interleukin-15 (IL-15) and the absence of TCR activation or co-stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non-haematopoietic tissue-resident ?? T cell expansion are provided, as well as populations of non-haematopoietic tissue-resident ?? T cells and uses thereof.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: April 4, 2023
    Inventors: Adrian Hayday, Oliver Nussbaumer, Richard Woolf
  • Patent number: 11612638
    Abstract: Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 28, 2023
    Assignees: Biokine Therapeutics Ltd., BioLineRx Ltd.
    Inventors: Amnon Peled, Yaron Pereg
  • Patent number: 11613569
    Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: March 28, 2023
    Assignees: CZ Biohub SF, LLC., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Derek Croote, Stephen R. Quake, Kari Nadeau, Spyros Darmanis, David N. Cornfield